These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 35902108)
1. Absolute and relative benefits of statins. Drug Ther Bull; 2022 Sep; 60(9):132. PubMed ID: 35902108 [No Abstract] [Full Text] [Related]
2. Estimate of time to benefit from bisphosphonate therapy. Drug Ther Bull; 2022 Jun; 60(6):87. PubMed ID: 35551098 [No Abstract] [Full Text] [Related]
3. International variation in approval of medicines. Drug Ther Bull; 2023 Apr; 61(4):51. PubMed ID: 36849223 [No Abstract] [Full Text] [Related]
4. The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Jamialahmadi T; Baratzadeh F; Reiner Ž; Simental-Mendía LE; Xu S; Susekov AV; Santos RD; Sahebkar A Mediators Inflamm; 2021; 2021():9661752. PubMed ID: 34526854 [TBL] [Abstract][Full Text] [Related]
5. Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. de Boer LM; Oorthuys AOJ; Wiegman A; Langendam MW; Kroon J; Spijker R; Zwinderman AH; Hutten BA Eur J Prev Cardiol; 2022 May; 29(5):779-792. PubMed ID: 34849724 [TBL] [Abstract][Full Text] [Related]
6. Non-fatal MI is not a surrogate for cardiovascular or all-cause mortality. Drug Ther Bull; 2022 Jun; 60(6):86. PubMed ID: 35444003 [No Abstract] [Full Text] [Related]
7. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766 [TBL] [Abstract][Full Text] [Related]
8. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N BMJ; 2022 May; 377():e069066. PubMed ID: 35508320 [TBL] [Abstract][Full Text] [Related]
10. Use of medicines that may raise BP in adults with hypertension. Drug Ther Bull; 2022 May; 60(5):70. PubMed ID: 35473817 [No Abstract] [Full Text] [Related]
11. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ; Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900 [TBL] [Abstract][Full Text] [Related]
12. No evidence that drugs reduce progression of osteoarthritis. Drug Ther Bull; 2022 Jan; 60(1):4. PubMed ID: 34893499 [No Abstract] [Full Text] [Related]
13. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Chatzizisis YS; Koskinas KC; Misirli G; Vaklavas C; Hatzitolios A; Giannoglou GD Drug Saf; 2010 Mar; 33(3):171-87. PubMed ID: 20158283 [TBL] [Abstract][Full Text] [Related]
14. Adding ezetimibe to statin therapy: latest evidence and clinical implications. Vavlukis M; Vavlukis A Drugs Context; 2018; 7():212534. PubMed ID: 30023003 [TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis. Hodkinson A; Tsimpida D; Kontopantelis E; Rutter MK; Mamas MA; Panagioti M BMJ; 2022 Mar; 376():e067731. PubMed ID: 35331984 [TBL] [Abstract][Full Text] [Related]
16. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Ulbricht C; Basch E; Szapary P; Hammerness P; Axentsev S; Boon H; Kroll D; Garraway L; Vora M; Woods J; Complement Ther Med; 2005 Dec; 13(4):279-90. PubMed ID: 16338199 [TBL] [Abstract][Full Text] [Related]
17. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. Chou R; Dana T; Blazina I; Daeges M; Jeanne TL JAMA; 2016 Nov; 316(19):2008-2024. PubMed ID: 27838722 [TBL] [Abstract][Full Text] [Related]
18. Risk of DKA with SGLT2 inhibitors. Drug Ther Bull; 2021 May; 59(5):69. PubMed ID: 33653729 [No Abstract] [Full Text] [Related]
19. Notice of Retraction: Panagioti et al. Association Between Physician Burnout and Patient Safety, Professionalism, and Patient Satisfaction: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018;178(10):1317-1331. Bauchner H; Redberg RF JAMA Intern Med; 2020 Jul; 180(7):931. PubMed ID: 32421149 [No Abstract] [Full Text] [Related]